Literature DB >> 3512279

Characterization of the hematopoietic defect in paroxysmal nocturnal hemoglobinuria.

J G Moore, R K Humphries, M M Frank, N Young.   

Abstract

We studied the relationship between paroxysmal nocturnal hemoglobinuria (PNH) and bone marrow failure using in vitro hematopoietic colony culture assays. Most of 17 patients with PNH showed decreased colony formation, by erythroid burst-forming cells (BFU-E) and granulocyte-macrophage colony-forming cells (CFU-C) in methylcellulose, disproportionate to their degree of bone marrow biopsy cellularity. Only a minority of the hematopoietic progenitors were sensitive to complement-mediated lysis in vitro. In contrast, normoblasts from maturing erythroid bursts removed from culture and exposed to acidified serum were sensitive to complement-mediated lysis. The size of bursts and the sensitivity of their progeny correlated strongly, suggesting that the PNH defect was acquired in culture as a function of the generational age of erythroid precursor cells. In addition, BFU-E of PNH patients were very sensitive to 3H-thymidine suicide, in comparison with normal individuals and patients with other hemolytic anemias, indicating that a large proportion of primitive erythroid progenitors in PNH bone marrow were in cell cycle. All of these results imply that acquisition of the PNH defect during erythropoiesis may lead to intramedullary destruction of developing erythroid cells. The increased demand that results on the progenitor pool may lead to stem cell depletion and bone marrow failure.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3512279

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  8 in total

1.  Retrovirus-induced feline pure red cell aplasia. Hematopoietic progenitors are infected with feline leukemia virus and erythroid burst-forming cells are uniquely sensitive to heterologous complement.

Authors:  J L Abkowitz; R D Holly; C K Grant
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

2.  Combination of interleukins 3 and 6 preserves stem cell function in culture and enhances retrovirus-mediated gene transfer into hematopoietic stem cells.

Authors:  D M Bodine; S Karlsson; A W Nienhuis
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

Review 3.  New insights into molecular pathogenesis of bone marrow failure in paroxysmal nocturnal hemoglobinuria.

Authors:  Tatsuya Kawaguchi; Hideki Nakakuma
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

Review 4.  The relationship of aplastic anemia and PNH.

Authors:  Neal S Young; Jaroslaw P Maciejewski; Elaine Sloand; Guiben Chen; Weihua Zeng; Antonio Risitano; Akira Miyazato
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

5.  A knock-out model of paroxysmal nocturnal hemoglobinuria: Pig-a(-) hematopoiesis is reconstituted following intercellular transfer of GPI-anchored proteins.

Authors:  D E Dunn; J Yu; S Nagarajan; M Devetten; F F Weichold; M E Medof; N S Young; J M Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

6.  Phenotypic and functional characterization of a mouse model of targeted Pig-a deletion in hematopoietic cells.

Authors:  Valeria Visconte; Nalini Raghavachari; Delong Liu; Keyvan Keyvanfar; Marie J Desierto; Jichun Chen; Neal S Young
Journal:  Haematologica       Date:  2009-08-13       Impact factor: 9.941

7.  Acute myeloblastic leukemia in paroxysmal nocturnal hemoglobinuria. Evidence of evolution from the abnormal paroxysmal nocturnal hemoglobinuria clone.

Authors:  D V Devine; W L Gluck; W F Rosse; J B Weinberg
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

8.  Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation.

Authors:  C Sugimori; E Padron; G Caceres; K Shain; L Sokol; L Zhang; R Tiu; C L O'Keefe; M Afable; M Clemente; J M Lee; J P Maciejewski; A F List; P K Epling-Burnette; D J Araten
Journal:  Blood Cancer J       Date:  2012-03-23       Impact factor: 11.037

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.